Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

HER2-directed antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload

Trastuzumab Deruxtecan

ENHERTU

Dosage form
Tablet
Available strengths
100 mg/vial (reconstituted to 20 mg/mL)
Drug class
HER2-directed antibody-drug conjugate (ADC) with a topoisomerase I inhibitor payload
Common brand
ENHERTU

Clinical overview. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate (brand name ENHERTU) given by intravenous infusion every 3 weeks to treat several HER2-related cancers, including breast cancer, HER2-low breast cancer, gastric cancer, and other HER2-positive solid tumours. It works by delivering a chemotherapy payload directly into HER2-expressing cancer cells. Its most serious risks are interstitial lung disease and pneumonitis, which can be fatal, along with reduced heart pumping function, low blood cell counts, and serious harm to a developing fetus, so patients require regular lung, heart, and blood monitoring throughout treatment.

Indication

Common therapeutic uses

  • Trastuzumab deruxtecan (ENHERTU) is used alone to treat adults with unresectable or metastatic HER2-positive breast cancer who have already received at least one prior anti-HER2 treatment regimen, either for metastatic disease or with recurrence within 6 months of completing earlier treatment.
  • It is used alone for HER2-positive breast cancer that has previously been treated with trastuzumab emtansine.
  • It is used alone for hormone receptor-positive, HER2-low or HER2-ultralow breast cancer in patients who have had at least one endocrine therapy and are no longer considered candidates for further endocrine treatment.
  • It is used alone for HER2-low breast cancer after at least one prior chemotherapy regimen for metastatic disease, or recurrence within 6 months of completing adjuvant chemotherapy.
  • It is used alone for unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma after a prior trastuzumab-based treatment regimen.
  • It is used alone for unresectable or metastatic HER2-positive (IHC 3+) solid tumours in patients who have had prior systemic treatment and have no satisfactory alternative options.
  • Treatment requires laboratory confirmation of the tumour's HER2 status using a validated test before starting therapy.

Pregnancy

Risk assessment and monitoring considerations

  • Trastuzumab deruxtecan can cause serious harm to a developing fetus and should be avoided during pregnancy.
  • There is no human pregnancy data; post-marketing reports with trastuzumab, a related HER2-targeted antibody, describe low amniotic fluid, fatal lung underdevelopment, skeletal problems, and newborn death.
  • The topoisomerase I inhibitor component is also expected to cause fetal harm based on its mechanism of action and animal study findings.
  • Pregnancy status should be confirmed before starting treatment in patients who could become pregnant.
  • Effective contraception is required during treatment and for at least 7 months after the last dose in patients who could become pregnant, and for at least 4 months after the last dose for male patients with partners who could become pregnant.
  • Patients should contact their doctor immediately if pregnancy occurs during treatment or within 7 months of the last dose.

Breastfeeding

Infant exposure considerations

  • It is not known whether trastuzumab deruxtecan passes into human breast milk, though antibodies of this type are known to be present in human milk.
  • Breastfeeding should be discontinued before starting treatment, given the potential for serious harm to a nursing infant; it may be resumed about 7 months after the last dose.

Geriatrics

Dosing and tolerability considerations

  • No overall difference in effectiveness was seen between patients 65 years and older and younger patients.
  • Clinical experience suggests some differences in safety with increasing age, including a higher rate of treatment interruptions for adverse reactions.
  • No dose adjustment is required based on age alone.

Pediatrics

Use in children and adolescents

  • Safety and effectiveness in children and adolescents under 18 years of age have not been established, and no pediatric indication is authorized.

Dosage & Administration

Practical dosing and administration

  • For breast cancer and HER2-positive solid tumours, the recommended dose is 5.4 mg/kg given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity.
  • For gastric and gastroesophageal junction cancer, the recommended dose is 6.4 mg/kg given as an intravenous infusion once every 3 weeks until disease progression or unacceptable toxicity.
  • Patients should be premedicated with a combination antiemetic regimen before each dose, since nausea and vomiting, including delayed symptoms, are expected.
  • The first infusion is given over 90 minutes; later infusions may be shortened to 30 minutes if earlier doses were well tolerated.
  • Dose reductions follow a stepwise schedule with two permitted reduction levels; a need for a third reduction means treatment must be stopped.
  • Treatment is interrupted or the dose reduced for interstitial lung disease, neutropenia, febrile neutropenia, low platelet counts, or a significant drop in heart pumping function, with permanent discontinuation required for the most severe grades of these events.
  • If a planned dose is delayed or missed, it should be given as soon as possible rather than waiting for the next cycle, keeping doses roughly 3 weeks apart.
  • No dose adjustment is needed for mild or moderate kidney impairment, though patients with moderate impairment should be watched closely for lung problems; limited data exist for severe kidney impairment.
  • No dose adjustment is needed for mild liver impairment; patients with moderate impairment should be monitored closely for increased toxicity, and there is no data for severe liver impairment.
  • Trastuzumab deruxtecan must be reconstituted and diluted by a trained health professional and given only as an intravenous infusion through an in-line filter; it must never be given as a rapid injection or bolus.
  • Because the name and packaging can be confused with trastuzumab or trastuzumab emtansine, staff should double-check the vial label before preparing or giving each dose.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Information on trastuzumab deruxtecan overdose is limited.
  • In clinical studies, doses higher than the recommended dose were associated with a higher rate of severe adverse events.
  • There is no antidote for trastuzumab deruxtecan.
  • Management involves close patient monitoring and appropriate supportive care.

Common side effects

Frequently reported tolerability concerns

  • Nausea is very common.
  • Fatigue is common.
  • Vomiting is common.
  • Hair loss (alopecia) is common.
  • Low red blood cell counts (anemia) are common.
  • Low white blood cell counts (neutropenia) are common.
  • Constipation is common.
  • Decreased appetite is common.
  • Diarrhea is common.
  • Elevated liver enzymes may occur.
  • Musculoskeletal pain may occur.
  • Low platelet counts (thrombocytopenia) may occur.
  • Low white blood cell counts (leukopenia) may occur.
  • Headache may occur.
  • Abdominal pain may occur.
  • Blurred vision may occur.
  • Dizziness may occur.
  • Altered sense of taste (dysgeusia) may occur.
  • Nosebleeds (epistaxis) may occur.
  • Cough may occur.
  • Dry eyes may occur.
  • Weight loss may occur.
  • Mouth sores (stomatitis) may occur.
  • Upper respiratory tract infections may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Interstitial lung disease and pneumonitis, including fatal cases, have occurred and require permanent discontinuation once symptomatic.
  • A decrease in the heart's pumping ability (left ventricular dysfunction) and heart failure can occur.
  • Severe or febrile neutropenia can occur, increasing infection risk.
  • Severe thrombocytopenia can occur, increasing bleeding risk.
  • Infusion-related reactions, including serious hypersensitivity, have been reported.
  • Exposure during pregnancy can seriously harm a developing fetus.
  • There is a risk of dangerous medication errors from confusing this drug with trastuzumab or trastuzumab emtansine, which are dosed very differently.
  • Seek urgent medical attention for new or worsening cough, shortness of breath, fever, chest pain, an irregular heartbeat, or signs of a severe allergic reaction.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with moderate kidney impairment, who have a higher reported rate of lung-related adverse reactions.
  • Use with caution in patients with moderate liver impairment, given the potential for increased drug exposure and toxicity.
  • Use with caution in patients with a prior history of interstitial lung disease or pneumonitis.
  • Use with caution in patients with pre-existing heart disease or reduced heart pumping function, since this population has not been studied.
  • Use with caution in patients of Asian background, who have shown higher rates of low blood cell counts and bleeding events in clinical trials.
  • Exercise caution when driving or operating machinery, as fatigue, headache, and dizziness can occur.
  • Complete blood counts should be checked before starting treatment and before every dose.
  • Heart pumping function should be assessed before starting treatment and at regular intervals during treatment.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to trastuzumab deruxtecan or to any ingredient in the formulation.

Drug interactions

Clinically relevant combinations

  • Ritonavir, a combined transporter and CYP3A inhibitor, did not meaningfully increase drug exposure, so no dose adjustment is needed when co-administered.
  • Itraconazole, a strong CYP3A inhibitor, did not meaningfully increase drug exposure, so no dose adjustment is needed when co-administered.
  • No clinically meaningful interaction is expected with inhibitors of the P-glycoprotein, MATE2-K, MRP1, or BCRP drug transporters.
  • Trastuzumab deruxtecan's active payload does not inhibit or induce major liver drug-metabolizing enzymes, so it is unlikely to meaningfully change the levels of other drugs.

Food interactions

Meal-related administration

  • Trastuzumab deruxtecan is given only by intravenous infusion in a clinic setting, so food timing does not apply.
  • No interactions with food or herbal products have been established.

Time of administration

Practical scheduling

  • Given by intravenous infusion once every 3 weeks by a health professional; timing is not tied to meals or a specific time of day.
  • Patients are observed for a period after each infusion to check for reactions.

Storage

Product handling

  • Store vials refrigerated at 2°C to 8°C, protected from light; do not freeze or shake.
  • After reconstitution, use immediately, or refrigerate and use within the time limits set by the pharmacy; discard unused vials after the permitted refrigeration window.
  • Once diluted for infusion, use promptly, or store briefly at room temperature or refrigerated as directed, protected from light.

Patient take-away

Key counselling points for a quick closing summary

  • Trastuzumab deruxtecan (ENHERTU) is a targeted intravenous cancer therapy for several types of HER2-related breast, gastric, and other solid tumours.
  • Lung problems (interstitial lung disease) are a serious risk; report any new or worsening cough or shortness of breath right away.
  • Heart function is monitored regularly during treatment because of the risk of reduced pumping ability.
  • Effective contraception is required during treatment and for months afterward, since this medicine can seriously harm a developing fetus.
  • Seek urgent medical attention for breathing problems, chest pain, an irregular heartbeat, or signs of a severe allergic reaction.

References

Source material and product information

  1. Health Canada Product Monograph — Trastuzumab Deruxtecan

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.